SLNO Share Price Performance
US$41.53
-8.68 (-17.29%)
71.1% undervalued intrinsic discount
US$143.71
Fair Value
Price US$41.53
AnalystHighTarget US$143.71
AnalystConsensusTarget US$113.54
AnalystLowTarget US$83.36
Fair ValueUS$143.71
Share Pricen/a
Soleno Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
SLNO Community Narratives
AN
Fair Value US$143.71 71.1% undervalued intrinsic discount
First Mover In Prader Willi Treatment Will Transform Rare Disease Market Over Time
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$113.54 63.4% undervalued intrinsic discount
Rapid Payer Coverage And International Expansion Are Expected To Drive Long-Term Upside
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$83.36 50.2% undervalued intrinsic discount
Future Payer Pressure And Limited Prescriber Adoption Will Challenge Uptake Yet Leave Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
First Mover In Prader Willi Treatment Will Transform Rare Disease Market Over Time
Catalysts About Soleno Therapeutics Soleno Therapeutics develops and commercializes VYKAT XR, the first FDA approved treatment for hyperphagia in people with Prader Willi syndrome. What are the underlying business or industry changes driving this perspective?Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$143.71
71.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
131.23% p.a.
Profit Margin
77.22%
Future PE
12.32x
Price in 2029
US$178.51
Future Payer Pressure And Limited Prescriber Adoption Will Challenge Uptake Yet Leave Upside Potential
Catalysts About Soleno Therapeutics Soleno Therapeutics develops and commercializes therapies for patients with Prader Willi syndrome, focusing on treating hyperphagia and its complications. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$83.36
50.2% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
110.5% p.a.
Profit Margin
49.2%
Future PE
14.86x
Price in 2028
US$102.28
Rapid Payer Coverage And International Expansion Are Expected To Drive Long-Term Upside
Catalysts About Soleno Therapeutics Soleno Therapeutics develops and commercializes therapies for Prader-Willi syndrome, focusing on hyperphagia and its life-threatening complications. What are the underlying business or industry changes driving this perspective?Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$113.54
63.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
115.16% p.a.
Profit Margin
0.58%
Future PE
16.14x
Price in 2028
US$1.39
Trending Discussion
Recently Updated Narratives
AN
First Mover In Prader Willi Treatment Will Transform Rare Disease Market Over Time
Fair Value: US$143.71 71.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Future Payer Pressure And Limited Prescriber Adoption Will Challenge Uptake Yet Leave Upside Potential
Fair Value: US$83.36 50.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rapid Payer Coverage And International Expansion Are Expected To Drive Long-Term Upside
Fair Value: US$113.54 63.4% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Soleno Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.46
- 98.14%
- -79.50%
- 10.1%
About SLNO
- Founded
- 1999
- Employees
- 152
- CEO
- WebsiteView website
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
